Primary Vs. Secondary Hypogonadism In Men, Explained

Primary vs. secondary hypogonadism comes down to where the breakdown happens. Both types end in low testosterone. They start in different places. Primary hypogonadism is a problem inside the testes. Secondary hypogonadism is a signaling failure in the brain, in the hypothalamus and pituitary gland. That distinction is not trivia. One type often impairs a man's fertility. The other can sometimes improve once its underlying cause is treated. Calling the problem "low T" and stopping there skips the part that actually shapes treatment.

Sorting the two apart starts with lab work, not symptoms alone. A telehealth hormone care team confirms the pattern with blood tests, then matches the plan to the cause.

What Is Male Hypogonadism?

Hypogonadism is the medical term for when the testes do not make enough testosterone, and sometimes not enough sperm. In primary hypogonadism, the testes cannot make enough even when the brain pushes them hard. In secondary hypogonadism, the testes can work, but the brain's signals are too weak to drive them. Blood tests separate the two.

Low testosterone is common, and it climbs with age. In the HIM study of men 45 and older visiting US primary care offices, 38.7% had a total testosterone under 300 ng/dL (Mulligan et al., 2006).

That figure deserves a caveat, though. It measured a lab value, not a diagnosis. A low number on its own does not equal hypogonadism, and plenty of men sit under 300 ng/dL with no symptoms at all. Guidelines require both a low level and real symptoms, which is why lab numbers and symptoms have to be read together. Symptoms sometimes linked to low testosterone include reduced sex drive, erectile difficulties, fatigue, low mood, and trouble concentrating, though each can have many other causes.

Primary Hypogonadism Starts in the Testes

Primary hypogonadism means the testes themselves cannot produce enough testosterone. The brain notices and signals harder, so luteinizing hormone (LH) and follicle-stimulating hormone (FSH) run high while testosterone stays low. Older texts call this primary testicular failure or hypergonadotropic hypogonadism.

Common causes include:

• Genetic conditions such as Klinefelter syndrome

• Mumps or other infections that damage the testes

• Radiation, chemotherapy, or other cancer treatment

• Testicular injury or undescended testicles

• Age-related decline in testicular function

Age belongs on that list, but with a flag. Testosterone falls slowly as men get older, and that gradual dip is not, on its own, a disease to be medicated. Testosterone is approved for low testosterone caused by a medical condition, not for aging by itself (FDA, 2025).

Secondary Hypogonadism Starts in the Brain

Secondary hypogonadism flips the location. The testes are capable, but the hypothalamus and pituitary do not send strong enough signals. So testosterone reads low while LH and FSH sit low or in the low-normal range. That pattern, low testosterone with normal or low LH, points the workup toward the brain rather than the testes.

It is also the more common type. In a 2025 study of men on therapy, central (secondary) hypogonadism was the reason for treatment 51% of the time, against 26% for primary (Neidhart et al., 2025). Drivers include obesity, type 2 diabetes, and sleep apnea, plus pituitary tumors, high prolactin, iron overload (hemochromatosis), head injury, heavy stress, opioid or anabolic steroid use, and genetic conditions like Kallmann syndrome.

Some of those causes are potentially reversible, and that is the practical difference. In some men, addressing factors like excess weight, sleep apnea, or certain medications may help the body's signaling recover, though results vary from person to person. Primary hypogonadism rarely reverses like that.

What's the Difference Between Primary and Secondary Hypogonadism?

The core difference is location and lab pattern. Primary hypogonadism comes from the testes and shows high LH and FSH. Secondary hypogonadism comes from the brain and shows low or low-normal LH and FSH. That one lab contrast drives most of the workup.

Do the Two Types Affect the Body Differently?

Day to day, the symptoms overlap. Both types may be associated with reduced libido, erectile difficulties, fatigue, muscle loss, and low mood, symptoms that can relate to low testosterone but often have other contributors. The differences show up underneath.

Primary hypogonadism more often brings fertility problems, low sperm counts, smaller testes, and sometimes breast tissue growth. Secondary hypogonadism usually travels with metabolic conditions: obesity, higher body fat, type 2 diabetes, and sleep apnea. That overlap is part of why treating those conditions can move testosterone in the right direction.

How Providers Tell Primary vs. Secondary Hypogonadism Apart

Both types look identical on a single testosterone test. The split comes from a wider panel, read in the right order. Providers confirm low testosterone first, then check LH and FSH to find where the problem sits.

Here is how providers usually sort it out:

1. Confirm low testosterone with more than one morning blood test, since a single reading is not enough (Mulhall et al., 2018).

2. Confirm symptoms alongside the low number. Both are needed, not a lab value on its own (Bhasin et al., 2018).

3. Measure LH and FSH. High points to the testes (primary). Low or low-normal points to the brain (secondary).

4. Add other tests as needed, such as prolactin, SHBG, and iron studies.

Blood Tests for Low Testosterone

Blood work is where the answer lives. The core panel is total testosterone, LH, FSH, and SHBG, with iron studies if there is reason to suspect overload. LH and FSH are the tell, since they show whether the testes or the brain is the source.

Total and free testosterone are not interchangeable, and a "normal" total can still hide a low free level. That is why free and total testosterone sometimes both need checking before anyone reaches a conclusion.

When Genetic Testing Helps

Genetic testing comes in when a born-with cause is likely. A karyotype can spot chromosome patterns like Klinefelter syndrome, the most common genetic cause of primary hypogonadism. Most men never need it. It earns its place when a younger man has very low testosterone paired with high FSH.

When Imaging Is Needed

Imaging targets the brain. When labs point to a secondary cause, especially with high prolactin or a very low testosterone, an MRI of the pituitary can check for a tumor. It is not routine. Most secondary cases trace back to obesity or medications rather than a growth.

How Is Each Type Treated?

Treatment follows the cause, which is the whole reason the primary-versus-secondary split matters. Both types can use testosterone therapy. Only one of them has fertility-sparing options, because those treatments depend on a brain that can still respond, and their effect varies by individual. And because testosterone is a controlled substance, it is prescribed only after lab confirmation and a real clinical evaluation, with telehealth access allowed on a temporary basis that varies by state.

Treating Primary Hypogonadism

When the testes have failed, replacing the missing hormone is usually the plan, and usually for the long term. Testosterone therapy comes in several forms, including injections, gels, and patches.

One catch matters here. Testosterone therapy itself suppresses sperm production. For a man with primary hypogonadism who wants children, that is a real conversation to have before starting, since the testes are already the weak link. Drugs for erectile dysfunction do not raise testosterone, but they can help that specific symptom when low testosterone is part of the picture.

Treating Secondary Hypogonadism

Secondary hypogonadism opens more doors, because the testes still work. Step one is treating the cause: weight loss, better sleep, managing diabetes, or stopping a medication that is suppressing the signal.

When medication is needed, fertility-sparing options exist. Selective estrogen receptor modulators such as clomiphene and drugs like enclomiphene may help the body make its own testosterone while generally preserving sperm production. Human chorionic gonadotropin works in a similar direction. Aromatase inhibitors like anastrozole help in specific cases by lowering estrogen. Several of these are used off-label, so they belong in a provider's hands, not a self-built protocol.

What Monitoring Does Testosterone Therapy Need?

Testosterone therapy is not set-and-forget. It needs regular lab checks, whichever type is being treated.

The big one is red blood cell concentration. Testosterone can push hematocrit up, and in a 2025 study of men on therapy, 23% passed a hematocrit of 50% and 5% went over 54% (Neidhart et al., 2025). Providers monitor for this during treatment and adjust the plan when needed (Bhasin et al., 2018), which is why managing hematocrit is built into follow-up.

Other checks include PSA for prostate safety, estradiol when symptoms suggest it, and blood pressure. The FDA added a blood pressure warning to all testosterone labels in 2025, based on monitoring studies (FDA, 2025). On the cardiovascular side, the TRAVERSE trial in men treated for diagnosed hypogonadism found that testosterone did not increase major cardiac events compared with placebo, though the testosterone group had more irregular heart rhythms and blood clots (Lincoff et al., 2023). Those findings apply to treatment that is medically indicated, not to testosterone use in general. After the trial, the FDA removed the older heart-risk boxed warning while keeping its other cautions in place.

The Bottom Line on Low Testosterone Types

Primary and secondary hypogonadism end at the same symptom, low testosterone, but they are different problems that call for different plans. Primary starts in the testes and usually means long-term testosterone therapy. Secondary starts in the brain, often ties back to weight, sleep, or medications, and can sometimes be corrected without lifelong treatment at all. Treating every man with a low number as a permanent testosterone patient gets the order wrong.

For any man with symptoms, the best step is the same: talk with a licensed provider about whether testing makes sense and what the results would mean for him. Understanding primary vs. secondary hypogonadism is what turns a vague "low T" label into a plan that fits the cause.

Disclaimer: This blog post is intended for informational purposes only and should not be considered medical advice. Always consult a healthcare professional before making changes to your health routine.

FAQs

What is the difference between primary vs. secondary hypogonadism? 

The difference is location. Primary hypogonadism is a problem in the testes, which show up on labs as high LH and FSH with low testosterone. Secondary hypogonadism is a brain signaling problem, with low or low-normal LH and FSH. A diagnosis still needs symptoms plus a confirmed low testosterone level, not a single number.

Which type of hypogonadism is more common? 

Secondary (central) hypogonadism is the more common type seen in treatment. In one 2025 study of men on testosterone therapy, 51% had secondary hypogonadism versus 26% with primary. It is closely linked to obesity, type 2 diabetes, and sleep apnea.

Can secondary hypogonadism be reversed? 

Sometimes. When secondary hypogonadism comes from a reversible factor such as excess weight, sleep apnea, or certain medications, treating that cause may help the body's testosterone recover in some men. Other causes are not reversible, so the outcome depends on the individual. Primary hypogonadism rarely reverses, since the testes themselves are the limiting factor.

How do doctors test for primary vs. secondary hypogonadism? 

Providers usually confirm low testosterone with more than one morning blood test before making a diagnosis. They then check LH and FSH to locate the problem: high values point to the testes, while low or low-normal values point to the brain. Symptoms also need to be present, not lab numbers alone.

Does testosterone therapy cause infertility? 

Testosterone therapy suppresses the body's own sperm production and can reduce fertility while it is being used. For men who want children, especially with secondary hypogonadism, fertility-sparing options such as enclomiphene or hCG may be used instead of or alongside standard therapy. This is a conversation to have with a provider before starting.

What are the risks of testosterone therapy? 

The most common lab risk is a rise in red blood cell concentration; in a 2025 study, 5% of men on therapy exceeded a hematocrit of 54%, the level guidelines flag for action. Other monitored risks include increased blood pressure, which the FDA added to testosterone labels in 2025, and prostate changes tracked with PSA testing. Regular lab follow-up is part of safe treatment.

References

• Int J Clin Pract. 2006;60(7):762–769

• U.S. Food and Drug Administration. Class-wide labeling changes for testosterone products. 2025

• Front Endocrinol (Lausanne). 2025;15:1496906

• J Urol. 2018;200(2):423–432

• J Clin Endocrinol Metab. 2018;103(5):1715–1744

• N Engl J Med. 2023;389(2):107–117